Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Convertible Debt (2023)

Zenas BioPharma has reported Convertible Debt over the past 1 years, most recently at $20.3 million for Q4 2023.

  • Quarterly results put Convertible Debt at $20.3 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $20.3 million (changed N/A YoY), and the annual figure for FY2023 was $20.3 million, changed.
  • Convertible Debt for Q4 2023 was $20.3 million at Zenas BioPharma.
  • Over the last five years, Convertible Debt for ZBIO hit a ceiling of $20.3 million in Q4 2023 and a floor of $20.3 million in Q4 2023.